Aiwu Ruth He, MD, Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USA, discusses an exploratory subgroup analysis of the randomized, double-blind, global Phase III TOPAZ-1 study (NCT03875235) by primary tumor location. In the TOPAZ-1 study, patients with locally advanced or metastatic biliary tract cancer were randomised to receive durvalumab plus chemotherapy (gemcitabine and cisplatin) or placebo plus chemotherapy for 8 cycles, followed by durvalumab or placebo monotherapy. Dr He comments on the results of this analysis by primary tumor location, namely that the durvalumab group had a statistically significant improvement in overall survival (OS) and that this improved clinical benefit was observed across different primary tumor locations. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.
